•Anthropic blocked access to its Fable 5 and Mythos 5 models after the U.S. government flagged them as a security threat when used by foreign nationals.
•China's commerce ministry expressed strong dissatisfaction over the U.S. adding major Chinese tech firms to a Pentagon list of military-linked entities.
•The US FDA approved AstraZeneca's TRUQAP (capivasertib) as the first targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer.
•The FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for the adjuvant treatment of patients with clear cell renal cell carcinoma.
•Norsk Hydro declared a second force majeure on aluminium sales from Qatar following an unexpected termination of a marketing agreement by the Qatalum joint venture.
